|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
|
26011589 |
2015 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
|
26011589 |
2015 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
We have identified xIAP and cIAP1 as molecular targets of ceramide and determined that ceramide analog LCL85 is an effective sensitizer in overcoming resistance of human cell lines established from metastatic colon and breast cancers to apoptosis induction to suppress metastasis in vivo.
|
24422988 |
2014 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
CTD_human |
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
|
25330770 |
2014 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Moreover, exposure of NB and breast cancer cells to CFM-4 or -5 resulted in diminished expression of anti-apoptotic XIAP1, cIAP1, and Survivin proteins.
|
25033461 |
2014 |
|
Breast Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Moreover, exposure of NB and breast cancer cells to CFM-4 or -5 resulted in diminished expression of anti-apoptotic XIAP1, cIAP1, and Survivin proteins.
|
25033461 |
2014 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression.
|
24422988 |
2014 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
|
25330770 |
2014 |
|
leukemia
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Our data demonstrate that ARC is regulated via BIRC2/MAP3K14 signalling and its overexpression in AML or MSCs can function as a resistant factor to birinapant-induced leukaemia cell death, suggesting that strategies to inhibit ARC will improve the therapeutic potential of SMAC mimetics.
|
25079338 |
2014 |
|
Stomach Neoplasms
|
0.310 |
AlteredExpression
|
group |
LHGDN |
Modulation of anti-apoptosis by endogenous IAP expression in MKN45 human gastric cancer cells.
|
16080516 |
2005 |
|
Stomach Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells.
|
14647439 |
2004 |
|
leukemia
|
0.310 |
Biomarker
|
disease |
CTD_human |
A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
|
12970779 |
2003 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
|
25330770 |
2014 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
|
25330770 |
2014 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
|
25330770 |
2014 |
|
Malignant neoplasm of stomach
|
0.300 |
Biomarker
|
disease |
CTD_human |
Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells.
|
14647439 |
2004 |
|
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells.
|
14647439 |
2004 |
|
HIV Infections
|
0.300 |
Biomarker
|
group |
CTD_human |
Anti-HIV activity of olive leaf extract (OLE) and modulation of host cell gene expression by HIV-1 infection and OLE treatment.
|
12878215 |
2003 |
|
HIV Coinfection
|
0.300 |
Biomarker
|
disease |
CTD_human |
Anti-HIV activity of olive leaf extract (OLE) and modulation of host cell gene expression by HIV-1 infection and OLE treatment.
|
12878215 |
2003 |
|
Leukemia, Myelocytic, Acute
|
0.120 |
AlteredExpression
|
disease |
BEFREE |
No statistically significant differences were found between the studied genes and prognosis stratifications, but Bcl-xl, Bak, cIAP1, and Mcl-1, LC3 were expressed at lower levels in the unfavorable AML group compared to the controls.
|
31434075 |
2020 |
|
Leukemia, Myelocytic, Acute
|
0.120 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.120 |
Biomarker
|
disease |
BEFREE |
Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
|
25079338 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In our TMA, cIAP1 was overexpressed in HNSCC compared with normal tissues (<i>P</i> = 0.0003) and associated with a poor overall survival (<i>P</i> = 0.0402). cIAP1 levels were higher in HPV<sup>-</sup> than that in HPV<sup>+</sup>HNSCC tumors (<i>P</i> = 0.004) and patients with cIAP1<sup>+</sup>/HPV<sup>-</sup> HNSCC had the worst survival.
|
31015310 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, API-LP displayed higher systemic exposure than free API-1 in mice without apparent toxicity, resulting in an enhanced tumor inhibition in xenograft mice.
|
31367251 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our study provides an interesting example using chemical biological approaches for determining distinct biological consequences from inhibiting vs. activating an E3 ubiquitin ligase and suggests a potential broad therapeutic strategy for targeting c-MYC in cancer treatment by pharmacologically modulating cIAP1 E3 ligase activity.
|
30181285 |
2018 |